Sunmax Biotechnology Co

Sunmax Biotechnology Co EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of Sunmax Biotechnology Co (4728.TWO) as of Oct 21, 2026 is 27.97. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was 40.71 — a change of -31.30% (lower).

EV/FCF

27.97

YoY

-31.30%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of Sunmax Biotechnology Co is 2025 27.97 . EV/FCF (Enterprise Value to Free Cash Flow) of Sunmax Biotechnology Co was 2024 40.71 . It decreases by -31.30% lower compared to the previous year.

The Sunmax Biotechnology Co EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2018
220.68 TWD
Jan 1, 2019
77.23 TWD
Jan 1, 2020
79.44 TWD
Jan 1, 2021
-1,696.66 TWD
Jan 1, 2022
107.01 TWD
Jan 1, 2023
27.63 TWD
Jan 1, 2024
40.71 TWD
Jan 1, 2025
27.97 TWD
The Sunmax Biotechnology Co EV/FCF history
YEAREV/FCFYoY
27.97-31.30%
40.71+47.34%
27.63-74.18%
107.01-106.31%
-1,696.66-2,235.75%
79.44+2.86%
77.23-65.00%
220.68-64.69%
624.98-65.03%
1,787.25-325.47%
-792.69-201.24%
782.99—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Sunmax Biotechnology Co Stock analysis

What does Sunmax Biotechnology Co do? SunMax Biotechnology Co., Ltd. generates revenue through the development, manufacturing, and commercialization of medical devices, biomedical materials, and bio surgical products. Its major products include collagen, collagen implants, microfiber collagen hemostat, collagen absorbable hemostat pads, healthcare products, and medical collagen application equipment. These products are sold to customers in the medical and beauty care industries across Taiwan, Mainland China, and other regions. The company's distribution focuses on these key markets, leveraging its product portfolio for healthcare and aesthetic applications. The firm's product line targets both medical and beauty care sectors, with collagen-based solutions serving as core offerings. Medical collagen application equipment supports clinical procedures, while collagen implants and hemostat products address surgical and wound care needs. The company's presence in Taiwan, Mainland China, and other regions enables it to serve diverse healthcare markets with standardized product offerings. SunMax Biotechnology's revenue streams are derived from the sale of collagen-based medical devices and equipment, with a focus on applications in surgery, wound care, and aesthetic treatments. By distributing its products through established channels in Taiwan, Mainland China, and other regions, the company capitalizes on demand for biocompatible materials in healthcare and beauty care industries. Sunmax Biotechnology Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Sunmax Biotechnology Co stock

EV/FCF (Enterprise Value to Free Cash Flow) of Sunmax Biotechnology Co is 27.97 in 2025.

EV/FCF (Enterprise Value to Free Cash Flow) of Sunmax Biotechnology Co changed from 40.71 to 27.97, representing a -31.30% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) Sunmax Biotechnology Co since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s Sunmax Biotechnology Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Sunmax Biotechnology Co

All Key Metrics — Sunmax Biotechnology Co